NASDAQ:APVO - Nasdaq - US03835L4059 - Common Stock - Currency: USD
0.74
+0.05 (+6.72%)
The current stock price of APVO is 0.74 USD. In the past month the price decreased by -58.66%. In the past year, price decreased by -97.17%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 17.5 | 313.20B | ||
AMGN | AMGEN INC | 14.02 | 149.41B | ||
GILD | GILEAD SCIENCES INC | 23.08 | 132.62B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 1698 | 126.59B | ||
REGN | REGENERON PHARMACEUTICALS | 12.88 | 64.26B | ||
ARGX | ARGENX SE - ADR | 319.7 | 36.31B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 31.48B | ||
BNTX | BIONTECH SE-ADR | N/A | 27.60B | ||
ONC | BEIGENE LTD-ADR | N/A | 26.85B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 24.51B | ||
NTRA | NATERA INC | N/A | 20.08B | ||
BIIB | BIOGEN INC | 7.17 | 17.30B |
Aptevo Therapeutics, Inc. is a clinical-stage biotechnology company, which engages on developing novel immunotherapies for the treatment of cancer. The company is headquartered in Seattle, Washington and currently employs 37 full-time employees. The company went IPO on 2016-07-20. The firm has two clinical candidates: Mipletamig and ALG.APV-527. Mipletamig is being evaluated in RAINIER, a two-part Phase 1b/2 trial for the treatment of frontline acute myeloid leukemia in combination with standard-of-care venetoclax + azacitidine. Mipletamig has received orphan drug designation for AML according to the Orphan Drug Act. ALG.APV-527, a bispecific conditional 4-1BB agonist, only active upon simultaneous binding to 4-1BB and 5T4, is being co-developed with Alligator Bioscience and is being evaluated in a Phase 1 clinical trial for the treatment of multiple solid tumor types likely to express 5T4. The firm has three pre-clinical candidates with different mechanisms of action designed to target a range of solid tumors. All pipeline candidates are created from two proprietary platforms, ADAPTIR and ADAPTIR-FLEX.
APTEVO THERAPEUTICS INC
2401 4th Ave Ste 1050
Seattle WASHINGTON 98121 US
CEO: Marvin L. White
Employees: 40
Company Website: https://aptevotherapeutics.com/
Investor Relations: http://aptevotherapeutics.gcs-web.com/financial-reports/sec-filings
Phone: 12068380500
The current stock price of APVO is 0.74 USD. The price increased by 6.72% in the last trading session.
The exchange symbol of APTEVO THERAPEUTICS INC is APVO and it is listed on the Nasdaq exchange.
APVO stock is listed on the Nasdaq exchange.
7 analysts have analysed APVO and the average price target is 21.42 USD. This implies a price increase of 2794.59% is expected in the next year compared to the current price of 0.74. Check the APTEVO THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
APTEVO THERAPEUTICS INC (APVO) has a market capitalization of 2.38M USD. This makes APVO a Nano Cap stock.
APTEVO THERAPEUTICS INC (APVO) currently has 40 employees.
APTEVO THERAPEUTICS INC (APVO) has a resistance level at 1. Check the full technical report for a detailed analysis of APVO support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
APVO does not pay a dividend.
APTEVO THERAPEUTICS INC (APVO) will report earnings on 2025-05-06.
APTEVO THERAPEUTICS INC (APVO) does not have a PE ratio as the earnings reported over the last twelve months were negative (-530.07).
The outstanding short interest for APTEVO THERAPEUTICS INC (APVO) is 4.11% of its float. Check the ownership tab for more information on the APVO short interest.
ChartMill assigns a fundamental rating of 2 / 10 to APVO. APVO scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
Over the last trailing twelve months APVO reported a non-GAAP Earnings per Share(EPS) of -530.07. The EPS decreased by -713.99% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -167.24% | ||
ROE | -559.13% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 83% to APVO. The Buy consensus is the average rating of analysts ratings from 7 analysts.